Canada's Protiva Biotherapeutics dropped litigation against Merck subsidiary Sirna Therapeutics when it inked a deal to share its RNAi technology with the pharma giant. Protiva has developed Stable Nucleic Acid-Lipid Particles, or SNALPs, that are used to deliver interfering RNA to cells. Protiva landed an undisclosed upfront fee and a royalty share on any new therapies that use the technology.
- see this release
Related Articles:
Merck to shell out $1.1B for Sirna. Report
Sirna pushing RNAi field. Report
A billion-dollar lesson in RNAi economics. Report
Read more on: Merck | Sirna | RNAi